Bristol-Myers Squibb stock kpis
Want to see BMY full AI Analyst Report?
Revenue by Segment
Bristol-Myers Squibb reported revenue by segment of $13.07B in Q3 2026, up 0.7% from Q2 2026 and up 6.9% year over year. This is the highest value since 2019.
Analyzes revenue from different business segments, highlighting which areas drive growth and profitability, and indicating how well the company diversifies its income streams.
Product revenue has shifted from steady to accelerating in H1‑2026, reflecting the Eliquis-led and broader growth‑portfolio strength that underpins management’s raised guidance; this makes product performance the primary driver of near‑term upside. “Other” has become a noticeably lumpier but slightly larger contributor since late‑2024, adding volatility rather than scale, while Alliance receipts are flat-to-declining, signaling limited partner upside. The stock’s path now hinges on sustaining Eliquis/growth product momentum and successful launches—legacy generic pressure and Opdivo softness remain the main downside risks.
BMY Revenue by Segment
| Period | Other | Product | Alliance | Total |
|---|---|---|---|---|
| Q3 2026Sep 30, 2026 | $368.00M | $12.61B | $95.00M | $13.07B |
| Q2 2026Jun 30, 2026 | $281.00M | $12.59B | $104.00M | $12.97B |
| Q1 2026Mar 31, 2026 | $227.00M | $11.17B | $94.00M | $11.49B |
| Q4 2025Dec 31, 2025 | $277.00M | $12.11B | $115.00M | $12.50B |
| Q3 2025Sep 30, 2025 | $247.00M | $11.85B | $125.00M | $12.22B |
| Q2 2025Jun 30, 2025 | $241.00M | $11.91B | $119.00M | $12.27B |
| Q1 2025Mar 31, 2025 | $227.00M | $10.89B | $88.00M | $11.20B |
| Q4 2024Dec 31, 2024 | $407.00M | $11.81B | $124.00M | $12.34B |
| Q3 2024Sep 30, 2024 | $304.00M | $11.48B | $105.00M | $11.89B |
| Q2 2024Jun 30, 2024 | $160.00M | $11.93B | $116.00M | $12.20B |
| Q1 2024Mar 31, 2024 | $172.00M | $11.56B | $134.00M | $11.87B |
| Q4 2023Dec 31, 2023 | $162.00M | $11.17B | $147.00M | $11.48B |
| Q3 2023Sep 30, 2023 | $183.00M | $10.64B | $138.00M | $10.97B |
| Q2 2023Jun 30, 2023 | $130.00M | $10.92B | $179.00M | $11.23B |
| Q1 2023Mar 31, 2023 | $145.00M | $11.05B | $144.00M | $11.34B |
| Q4 2022Dec 31, 2022 | $159.00M | $11.06B | $182.00M | $11.41B |
| Q3 2022Sep 30, 2022 | $232.00M | $10.81B | $173.00M | $11.22B |
| Q2 2022Jun 30, 2022 | $203.00M | $11.48B | $199.00M | $11.89B |
| Q1 2022Mar 31, 2022 | $152.00M | $11.31B | $188.00M | $11.65B |
| Q4 2021Dec 31, 2021 | $155.00M | $11.61B | $221.00M | $11.98B |
| Q3 2021Sep 30, 2021 | $187.00M | $11.24B | $194.00M | $11.62B |
| Q2 2021Jun 30, 2021 | $139.00M | $11.40B | $159.00M | $11.70B |
| Q1 2021Mar 31, 2021 | $133.00M | $10.80B | $142.00M | $11.07B |
| Q4 2020Dec 31, 2020 | $139.00M | $10.77B | $163.00M | $11.07B |
| Q3 2020Sep 30, 2020 | $159.00M | $10.20B | $184.00M | $10.54B |
| Q2 2020Jun 30, 2020 | $149.00M | $9.82B | $163.00M | $10.13B |
| Q1 2020Mar 31, 2020 | $135.00M | $10.54B | $105.00M | $10.78B |
| Q4 2019Dec 31, 2019 | $104.00M | $7.66B | $179.00M | $7.95B |
| Q3 2019Sep 30, 2019 | $96.00M | $5.77B | $143.00M | $6.01B |
| Q2 2019Jun 30, 2019 | $96.00M | $6.03B | $146.00M | $6.27B |
| Q1 2019Mar 31, 2019 | $78.00M | $5.71B | $129.00M | $5.92B |

